The novel platform was already being used for developing new thrombolytics to treat stroke and study bioluminescent enzyme evolution. In addition, in March 2021, the Loschmidt laboratories team, together with partners from ETH Zurich, developed a microfluidic platform for an effective and rapid investigation of enzymes and their properties. The laser-aided microfluidic irrigation tool offers an enhanced solution to existing disinfection and cleaning techniques, without interrupting process workflow or adding significant cost on a per-procedure basis. For instance, in January 2022, BIOLASE, Inc., and EdgeEndo received FDA 510(k) clearance for the EdgePRO system, intended for effective disinfection and cleaning alternative within root canal processes. Many companies have their devices under trial and are anticipated for commercialization. With the increasing penetration of microfluidics devices in various fields of research and diagnosis, advanced technologies are introduced by industry players to grab a potential market share. SigTuple combined AI, robotics, microfluidics, and cloud computing to develop smart diagnostic solutions to make quality healthcare delivery accessible and affordable. In August 2022, HORIBA announced a collaboration with SigTuple to speed up the deployment of its AI100, an AI-assisted digital pathology solution, in the Indian subcontinent. With advancements in technology, digital microfluidics is being explored by several key players. Moreover, market players, such as Abbott, Roche, and Danaher, have already incorporated microfluidics technology in their existing diagnostic devices. Microfluidics has thus made its mark in the IVD market. ![]() With improved technologies, market players now distinguish their products using minimally invasive features along with accuracy and speed. The point-of-care diagnostics introduced by numerous market players led to early disease diagnosis and reduced hospital visits. The application of microfluidics has allowed conventional laboratory procedures to be miniaturized onto a lab-on-a-chip. Microfluidics devices need a very small volume of samples for data interpretation. The conventional method of genome analysis requires decoding the entire DNA, thus adding to the cost of analysis and time. A surge in research activities undertaken by analytical and clinical researchers has also driven the demand for microfluidics devices. The introduction of microfluidics devices has driven the demand for low-volume sample devices. This reduces the amount of reagent waste and helps preserve samples that are difficult to produce. The major advantage of microfluidics devices is their ability to analyze small volumes of samples. It concluded that rapid PCR can be achieved with the use of emerging state-of-the-art microfluidics for SARS-CoV-2 detection. A study was published in June 2021 by researchers in China that demonstrated the use of the latest rapid microfluidic PCR. Furthermore, various studies are being conducted to evaluate the use of microfluidics in COVID-19 detection by PCR technique. This product is based on Fastgen technology and leverages the advantages of microfluidics to deliver test results in less than 30 minutes. When coupled with microfluidics, the PCR technique can be accelerated, which, in turn, provides faster test results (from approximately 1 hour to less than 10 minutes) with high accuracy.įor instance, BeforCure, a spin-off company from Elvesys, developed an ultra-fast PCR-on-chip system for the detection of the virus. ![]() To combat the rising cases of COVID-19 globally, several manufacturers have introduced products and ramped up their production to address the growing demand for IVD tests. ![]() Many approved tests are based on PCR, making it a preferred technique for COVID-19 diagnosis. Such applications are expected to positively affect the microfluidics market growth in the coming years.Īn exponential rise in COVID-19 cases globally boosted the demand for microfluidics tools. Microfluidic approaches have been effectively used to determine glucose levels, detect infection, diagnose dry eye disease, and assess levels of vascular endothelium growth factor. For instance, there has been an improvement in the number of microfluidic devices applicable to ophthalmological conditions over the past decade. The increasing penetration of microfluidics devices in various fields of research and diagnosis is expected to drive the market. The global microfluidics market size was valued at USD 23.57 billion in 2021 and is expected to expand at a CAGR of 12.16% from 2022 to 2030.
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |